ofloxacin has been researched along with Obesity in 2 studies
Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.
ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| "This is the first study to show a positive association of enrofloxacin internal exposure with overweight or obesity risk in children, demonstrating that more attention should be given to the usage and disposal of fluoroquinolones to safeguard children's health." | 4.12 | Association between fluoroquinolone exposure and children's growth and development: A multisite biomonitoring-based study in northern China. ( Gao, M; Li, H; Li, W; Pan, X; Shan, L; Tian, H; Wang, J, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shan, L | 1 |
| Gao, M | 1 |
| Pan, X | 1 |
| Li, W | 1 |
| Wang, J | 1 |
| Li, H | 1 |
| Tian, H | 1 |
| Cook, AM | 1 |
| Martin, C | 1 |
| Adams, VR | 1 |
| Morehead, RS | 1 |
1 trial available for ofloxacin and Obesity
| Article | Year |
|---|---|
Pharmacokinetics of intravenous levofloxacin administered at 750 milligrams in obese adults.
Topics: Adult; Anti-Bacterial Agents; Drug Administration Schedule; Female; Humans; Injections, Intravenous; | 2011 |
1 other study available for ofloxacin and Obesity
| Article | Year |
|---|---|
Association between fluoroquinolone exposure and children's growth and development: A multisite biomonitoring-based study in northern China.
Topics: Animals; Anti-Bacterial Agents; Biological Monitoring; Child; China; Ciprofloxacin; Enrofloxacin; Fl | 2022 |